Already a DIA Member? Sign in. Not a member? Join.

Iniciar sesión

¿Ha olvidado su ID de usuario? or ¿Ha olvidado su contraseña?

Not a Member?

Create Account and Join

Global Pediatric Policy Update: Are you Ready to Implement FDARA Section 504?

DIA members: Sign in below to see content options. Not a member? Enjoy this preview, then see below to join DIA today!

Read Full Transcript     Access Interactive Transcript     Listen and Download


Key Takeaways

  • FDARA Section 504 eliminated the orphan exemption for pediatric studies for cancer drugs and instead empowers the FDA to require pediatric assessments of new therapies when the molecular targets are substantially relevant to children’s cancers.
  • As shown in drug development programs in other therapeutic areas, public-private partnerships may increase efficiencies and reduce costs and may offer advantages for companies engaged in pediatric cancer research.
  • There's a growing acceptance of master protocols that use a single infrastructure, design, and protocol to simultaneously evaluate multiple drugs and/or disease populations in multiple sub-studies.
  • In addition to organizational and cost efficiencies, master protocols provide biopharma companies with a mechanism to prioritize their development portfolios.

Member Benefits

  • Full Video, Transcript and Audio-only Version Available

See All Insider Access Videos


This content is for DIA Members only. JOIN NOW for full access!

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.